Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the US, providing a new option ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first needle-free alternative to EpiPen-style autoinjectors for serious allergic reactions. The green light ...

Courtesy Lowenthal For decades, people suffering life-threatening allergic reactions had to quickly and correctly give ...

The platinum-selling rapper announced the birth of her first child on April 25 Flo Milli/Instagram Flo Milli has a bit of advice for anyone who is making negative comments about her motherhood or ...

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

ARS Pharmaceuticals (NASDAQ:SPRY) has signed a four-year agreement with ALK-Abelló A/S to co-promote neffy, its epinephrine ...